GLP-1 receptor agonists may lower acute pancreatitis recurrence risk in obese, type 2 diabetes patients, according to a study at Endocrine Society's annual meeting.

GLP-1 receptor agonist medications for type 2 diabetes and obesity may reduce acute pancreatitis recurrence risk in obese, type 2 diabetes patients, according to a study at Endocrine Society's annual meeting. Researchers analyzed a large database, finding GLP-1 group's lower risk compared to SGLT2 inhibitors or DPP4 inhibitors. This may change treatment landscape and highlight personalized medicine importance.